Return to homepagePandemic Pact

Prospective, randomized, parallel-group, open-label study to evaluate the efficacy and safety of IMU-838, in combination with oseltamivir, in adults with coronavirus - The IONIC Trial

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    University Hospitals Coventry & Warwickshire NHS Trust,

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

A clinical trial to investigate a combination of a host targeting agent, Immunic's DHODH inhibitor IMU-838, and an anti-viral drug, oseltamivir, for the treatment of hospitalised COVID-19 patients. 120 patients will be recruited in University Hospital Coventry & Warwickshire NHS Trust and other UK hospitals. Previous trials have shown DHODH inhibitors having a twofold effect on viral infection - decreasing the viral load and strengthening the innate immune response. Although oseltamivir, used for influenza, hasn't demonstrated efficacy for COVID-19, there have been promising effects in pre-clinical trials when these drugs have been used in combination